These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 27612194

  • 41. In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD.
    Sossi V, Holden JE, Topping GJ, Camborde ML, Kornelsen RA, McCormick SE, Greene J, Studenov AR, Ruth TJ, Doudet DJ.
    J Cereb Blood Flow Metab; 2007 Jul; 27(7):1407-15. PubMed ID: 17245418
    [Abstract] [Full Text] [Related]

  • 42. Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2.
    Kilbourn MR, Koeppe RA.
    ACS Chem Neurosci; 2019 Jan 16; 10(1):25-29. PubMed ID: 30198706
    [Abstract] [Full Text] [Related]

  • 43. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.
    Lin KJ, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Hsiao IT.
    PLoS One; 2013 Jan 16; 8(9):e75952. PubMed ID: 24098749
    [Abstract] [Full Text] [Related]

  • 44. Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter.
    Koeppe RA, Frey KA, Vander Borght TM, Karlamangla A, Jewett DM, Lee LC, Kilbourn MR, Kuhl DE.
    J Cereb Blood Flow Metab; 1996 Nov 16; 16(6):1288-99. PubMed ID: 8898703
    [Abstract] [Full Text] [Related]

  • 45. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
    Lin SC, Lin KJ, Hsiao IT, Hsieh CJ, Lin WY, Lu CS, Wey SP, Yen TC, Kung MP, Weng YH.
    J Nucl Med; 2014 Jan 16; 55(1):73-9. PubMed ID: 24287322
    [Abstract] [Full Text] [Related]

  • 46. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent.
    Lin KJ, Weng YH, Wey SP, Hsiao IT, Lu CS, Skovronsky D, Chang HP, Kung MP, Yen TC.
    J Nucl Med; 2010 Sep 16; 51(9):1480-5. PubMed ID: 20720042
    [Abstract] [Full Text] [Related]

  • 47. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
    Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE.
    Ann Neurol; 1996 Dec 16; 40(6):873-84. PubMed ID: 9007092
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations.
    Kilbourn MR, Butch ER, Desmond T, Sherman P, Harris PE, Frey KA.
    Nucl Med Biol; 2010 Jan 16; 37(1):3-8. PubMed ID: 20122661
    [Abstract] [Full Text] [Related]

  • 50. Visualizing pancreatic beta-cell mass with [11C]DTBZ.
    Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, Herron A, Kilbourn M, Jurewicz A, Herold K, Liu E, Hardy MA, Van Heertum R, Harris PE.
    Nucl Med Biol; 2006 Oct 16; 33(7):855-64. PubMed ID: 17045165
    [Abstract] [Full Text] [Related]

  • 51. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
    Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA.
    J Cereb Blood Flow Metab; 2006 Sep 16; 26(9):1198-212. PubMed ID: 16421508
    [Abstract] [Full Text] [Related]

  • 52. [18F]FP-(+)-DTBZ PET study in a lactacystin-treated rat model of Parkinson disease.
    Weng CC, Huang SL, Chen ZA, Lin KJ, Hsiao IT, Yen TC, Kung MP, Wey SP, Hsu CH.
    Ann Nucl Med; 2017 Aug 16; 31(7):506-513. PubMed ID: 28451991
    [Abstract] [Full Text] [Related]

  • 53. Diagnostic Utility of [11C]DTBZ Positron Emission Tomography In Clinically Uncertain Parkinsonism: Experience of a Single Tertiary Center.
    Pérez-Lohman C, Kerik NE, Díaz-Meneses IE, Cervantes-Arriaga A, Rodríguez-Violante M.
    Rev Invest Clin; 2018 Aug 16; 70(6):285-290. PubMed ID: 30532098
    [Abstract] [Full Text] [Related]

  • 54. Interpreting DTBZ binding data in rodent: Inherent variability and compensation.
    Mejias M, Yu J, Mackey S, Dinelle K, Sossi V, Doudet DJ.
    Synapse; 2016 Apr 16; 70(4):147-52. PubMed ID: 26749375
    [Abstract] [Full Text] [Related]

  • 55. Management Impact of Imaging Brain Vesicular Monoamine Transporter Type 2 in Clinically Uncertain Parkinsonian Syndrome with 18F-AV133 and PET.
    Alexander PK, Lie Y, Jones G, Sivaratnam C, Bozinvski S, Mulligan RS, Young K, Villemagne VL, Rowe CC.
    J Nucl Med; 2017 Nov 16; 58(11):1815-1820. PubMed ID: 28490469
    [Abstract] [Full Text] [Related]

  • 56. Synthesis of [11C]tetrabenazine, a vesicular monoamine uptake inhibitor, for PET imaging studies.
    DaSilva JN, Kilbourn MR, Mangner TJ.
    Appl Radiat Isot; 1993 Apr 16; 44(4):673-6. PubMed ID: 8472029
    [Abstract] [Full Text] [Related]

  • 57. In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.
    Narendran R, Lopresti BJ, Martinez D, Mason NS, Himes M, May MA, Daley DC, Price JC, Mathis CA, Frankle WG.
    Am J Psychiatry; 2012 Jan 16; 169(1):55-63. PubMed ID: 22193525
    [Abstract] [Full Text] [Related]

  • 58. Quantitative study of 18F-(+)DTBZ image: comparison of PET template-based and MRI based image analysis.
    Jung Lung H, Weng YH, Wen MC, Hsiao IT, Lin KJ.
    Sci Rep; 2018 Oct 30; 8(1):16027. PubMed ID: 30375444
    [Abstract] [Full Text] [Related]

  • 59. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
    Molinet-Dronda F, Gago B, Quiroga-Varela A, Juri C, Collantes M, Delgado M, Prieto E, Ecay M, Iglesias E, Marín C, Peñuelas I, Obeso JA.
    Neurobiol Dis; 2015 May 30; 77():165-72. PubMed ID: 25681534
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.